Juvenile myelomonocytic leukemia (JMML) is a unique clonal hematopoietic disorder of
early childhood. It is classified as an overlap myeloproliferative/myelodysplastic neoplasm …

Somatically acquired genetic abnormalities lead to the salient features that define
myelodysplastic syndromes (MDS): clonal hematopoiesis, aberrant differentiation …

To elucidate differential roles of mutations in myelodysplastic syndromes (MDS), we
investigated clonal dynamics using whole-exome and/or targeted sequencing of 699 …

Purpose Several prognostic scoring systems have been proposed for chronic
myelomonocytic leukemia (CMML), a disease in which some gene mutations—including …

Acute myeloid leukemia (AML) with t (8; 21) or inv (16) have been recognized as unique
entities within AML and are usually reported together as core binding factor AML (CBF …

Myelodysplastic syndromes (MDS) represent a heterogeneous group of neoplastic
hematopoietic disorders. Several recurrent chromosomal aberrations have been associated …

Background Transplantation of hematopoietic stem cells from partially matched family
donors is a promising therapy for patients who have a hematologic cancer and are at high …

The myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal
haematological diseases characterized by ineffective haematopoiesis and predisposition to …

The cytidine analogues azacytidine and 5-aza-2'-deoxycytidine (decitabine) are commonly
used to treat myelodysplastic syndromes, with or without a myeloproliferative component. It …

Myelodysplastic syndromes (MDSs) are chronic and often progressive myeloid neoplasms
associated with remarkable heterogeneity in the histomorphology and clinical course …